{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Sarilumab+200+MG%2F1.14+ML+Subcutaneous+Solution&page=2", "query": { "intervention": "Sarilumab 200 MG/1.14 ML Subcutaneous Solution", "page": 2 }, "page_size": 10 }, "pagination": { "page": 2, "page_size": 10, "total_count": 48, "total_pages": 5, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Sarilumab+200+MG%2F1.14+ML+Subcutaneous+Solution&page=3&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Sarilumab+200+MG%2F1.14+ML+Subcutaneous+Solution&page=1&page_size=10" }, "source": "remote", "last_synced_at": "2026-10-10T10:15:52.789Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT01328522", "title": "Comparison of the Safety and Pharmacokinetics of Two SAR153191 (REGN88) Drug Products in Rheumatoid Arthritis Patients", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Rheumatoid Arthritis" ], "interventions": [ { "name": "SAR153191 (REGN88)", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Sanofi", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "75 Years", "sex": "ALL", "summary": "18 Years to 75 Years" }, "enrollment_count": 32, "start_date": "2011-05", "completion_date": "2011-09", "has_results": false, "last_update_posted_date": "2011-10-24", "last_synced_at": "2026-10-10T10:15:52.789Z", "location_count": 4, "location_summary": "Beverly Hills, California • Ocala, Florida • Duncansville, Pennsylvania + 1 more", "locations": [ { "city": "Beverly Hills", "state": "California" }, { "city": "Ocala", "state": "Florida" }, { "city": "Duncansville", "state": "Pennsylvania" }, { "city": "Dallas", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT01328522" }, { "nct_id": "NCT01764997", "title": "An Evaluation of Sarilumab Plus Methotrexate Compared to Etanercept Plus Methotrexate in RA Patients Not Responding to Adalimumab Plus Methotrexate", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Rheumatoid Arthritis" ], "interventions": [ { "name": "Sarilumab", "type": "DRUG" }, { "name": "Etanercept", "type": "DRUG" }, { "name": "Methotrexate", "type": "DRUG" }, { "name": "Placebo (for sarilumab)", "type": "DRUG" }, { "name": "Placebo (for etanercept)", "type": "DRUG" }, { "name": "Adalimumab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Sanofi", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 776, "start_date": "2013-04", "completion_date": "2015-01", "has_results": true, "last_update_posted_date": "2017-07-27", "last_synced_at": "2026-10-10T10:15:52.789Z", "location_count": 30, "location_summary": "Birmingham, Alabama • Glendale, California • Thousand Oaks, California + 27 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Glendale", "state": "California" }, { "city": "Thousand Oaks", "state": "California" }, { "city": "Upland", "state": "California" }, { "city": "Victorville", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT01764997" }, { "nct_id": "NCT07154290", "title": "A Study to Investigate Ubamatamab With and Without Marlotamig (REGN7075) in Adult Participants With Advanced/Metastatic Non-Small Cell Lung Cancer (NSCLC)", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Non Small Cell Lung Cancer", "Advanced Non Small Cell Lung Cancer", "Metastatic Non Small Cell Lung Cancer", "Carcinoma Non Small Cell Lung" ], "interventions": [ { "name": "Ubamatamab", "type": "DRUG" }, { "name": "Marlotamig", "type": "DRUG" }, { "name": "Sarilumab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Regeneron Pharmaceuticals", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 300, "start_date": "2026-03-18", "completion_date": "2030-06-10", "has_results": false, "last_update_posted_date": "2026-09-25", "last_synced_at": "2026-10-10T10:15:52.789Z", "location_count": 17, "location_summary": "Birmingham, Alabama • Goodyear, Arizona • Irvine, California + 13 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Goodyear", "state": "Arizona" }, { "city": "Irvine", "state": "California" }, { "city": "Newark", "state": "Delaware" }, { "city": "Washington D.C.", "state": "District of Columbia" } ], "official_url": "https://clinicaltrials.gov/study/NCT07154290" }, { "nct_id": "NCT01768572", "title": "To Evaluate The Safety of SAR153191 (REGN88) and Tocilizumab Added to Other RA Drugs in Patients With RA Who Are Not Responding to or Intolerant of Anti-TNF Therapy (SARIL-RA-ASCERTAIN)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Rheumatoid Arthritis" ], "interventions": [ { "name": "sarilumab SAR153191 (REGN88)", "type": "DRUG" }, { "name": "tocilizumab", "type": "DRUG" }, { "name": "hydroxychloroquine", "type": "DRUG" }, { "name": "methotrexate", "type": "DRUG" }, { "name": "sulfasalazine", "type": "DRUG" }, { "name": "leflunomide", "type": "DRUG" }, { "name": "subcutaneous placebo", "type": "DRUG" }, { "name": "intravenous placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Sanofi", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 202, "start_date": "2013-03", "completion_date": "2014-10", "has_results": true, "last_update_posted_date": "2017-06-26", "last_synced_at": "2026-10-10T10:15:52.789Z", "location_count": 14, "location_summary": "Huntsville, Alabama • Colorado Springs, Colorado • Aventura, Florida + 10 more", "locations": [ { "city": "Huntsville", "state": "Alabama" }, { "city": "Colorado Springs", "state": "Colorado" }, { "city": "Aventura", "state": "Florida" }, { "city": "Fort Lauderdale", "state": "Florida" }, { "city": "Miami", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT01768572" }, { "nct_id": "NCT01061736", "title": "Evaluation of Sarilumab (SAR153191/REGN88) on Top of Methotrexate in Rheumatoid Arthritis Patients", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2", "PHASE3" ], "conditions": [ "Rheumatoid Arthritis" ], "interventions": [ { "name": "Sarilumab", "type": "DRUG" }, { "name": "Placebo (for sarilumab)", "type": "DRUG" }, { "name": "Methotrexate", "type": "DRUG" }, { "name": "Folic Acid", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Sanofi", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "75 Years", "sex": "ALL", "summary": "18 Years to 75 Years" }, "enrollment_count": 1675, "start_date": "2010-03", "completion_date": "2013-10", "has_results": true, "last_update_posted_date": "2017-06-28", "last_synced_at": "2026-10-10T10:15:52.789Z", "location_count": 45, "location_summary": "Anniston, Alabama • Birmingham, Alabama • Gilbert, Arizona + 39 more", "locations": [ { "city": "Anniston", "state": "Alabama" }, { "city": "Birmingham", "state": "Alabama" }, { "city": "Gilbert", "state": "Arizona" }, { "city": "Beverly Hills", "state": "California" }, { "city": "Palm Desert", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT01061736" }, { "nct_id": "NCT03600818", "title": "Evaluation of the Efficacy and Safety of Sarilumab in Patients With Polymyalgia Rheumatica", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Polymyalgia Rheumatica" ], "interventions": [ { "name": "Sarilumab SAR153191 (REGN88)", "type": "DRUG" }, { "name": "Sarilumab-matching placebo", "type": "DRUG" }, { "name": "Prednisone", "type": "DRUG" }, { "name": "Prednisone-matching placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Sanofi", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "50 Years", "maximum_age": null, "sex": "ALL", "summary": "50 Years and older" }, "enrollment_count": 118, "start_date": "2018-10-09", "completion_date": "2021-05-19", "has_results": true, "last_update_posted_date": "2022-06-10", "last_synced_at": "2026-10-10T10:15:52.789Z", "location_count": 10, "location_summary": "Upland, California • Denver, Colorado • Stamford, Connecticut + 7 more", "locations": [ { "city": "Upland", "state": "California" }, { "city": "Denver", "state": "Colorado" }, { "city": "Stamford", "state": "Connecticut" }, { "city": "Boca Raton", "state": "Florida" }, { "city": "Iowa City", "state": "Iowa" } ], "official_url": "https://clinicaltrials.gov/study/NCT03600818" }, { "nct_id": "NCT03378219", "title": "An Observational Study on Sarilumab-exposed Pregnancies", "overall_status": "COMPLETED", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "Rheumatoid Arthritis -Exposure During Pregnancy" ], "interventions": [ { "name": "Sarilumab SAR153191 (REGN88)", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Sanofi", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": null, "maximum_age": null, "sex": "FEMALE", "summary": "Female only" }, "enrollment_count": 113, "start_date": "2018-05-18", "completion_date": "2024-12-06", "has_results": false, "last_update_posted_date": "2025-01-17", "last_synced_at": "2026-10-10T10:15:52.789Z", "location_count": 1, "location_summary": "New York, New York", "locations": [ { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT03378219" }, { "nct_id": "NCT04008069", "title": "Sarilumab in Patients With Glucocorticoid-Dependent Sarcoidosis", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Sarcoidosis" ], "interventions": [ { "name": "Sarilumab", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Stanford University", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "80 Years", "sex": "ALL", "summary": "18 Years to 80 Years" }, "enrollment_count": 16, "start_date": "2019-09-03", "completion_date": "2022-09-09", "has_results": true, "last_update_posted_date": "2023-10-05", "last_synced_at": "2026-10-10T10:15:52.789Z", "location_count": 1, "location_summary": "Palo Alto, California", "locations": [ { "city": "Palo Alto", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT04008069" }, { "nct_id": "NCT04333706", "title": "A Dose Finding Phase 1 of Sarilumab Plus Capecitabine in HER2/Neu-Negative Metastatic Breast Cancer and a Single-arm, Historically-controlled Phase 2 Study of Sarilumab Plus Capecitabine in Stage I-III Triple Negative Breast Cancer With High-Risk Residual Disease (EMPOWER)", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Breast", "Metastatic", "Triple Negative", "Cancer", "Disseminated Tumor Cell" ], "interventions": [ { "name": "Capecitabine", "type": "DRUG" }, { "name": "Sarilumab 150mg or 200 mg plus Capecitabine", "type": "COMBINATION_PRODUCT" }, { "name": "Sarilumab 150mg plus Capecitabine", "type": "COMBINATION_PRODUCT" } ], "intervention_types": [ "DRUG", "COMBINATION_PRODUCT" ], "sponsor": "University of Southern California", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "99 Years", "sex": "ALL", "summary": "18 Years to 99 Years" }, "enrollment_count": 65, "start_date": "2020-09-26", "completion_date": "2027-05-03", "has_results": false, "last_update_posted_date": "2026-03-10", "last_synced_at": "2026-10-10T10:15:52.789Z", "location_count": 3, "location_summary": "Los Angeles, California • Gainesville, Florida", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Gainesville", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT04333706" }, { "nct_id": "NCT01042379", "title": "I-SPY TRIAL: Neoadjuvant and Personalized Adaptive Novel Agents to Treat Breast Cancer", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Breast Neoplasms", "Breast Cancer", "Breast Tumors", "Angiosarcoma", "TNBC - Triple-Negative Breast Cancer", "HER2-positive Breast Cancer", "HER2-negative Breast Cancer", "Hormone Receptor Positive Tumor", "Hormone Receptor Negative Tumor", "Early-stage Breast Cancer", "Locally Advanced Breast Cancer" ], "interventions": [ { "name": "Standard Therapy", "type": "DRUG" }, { "name": "AMG 386 with or without Trastuzumab", "type": "DRUG" }, { "name": "AMG 479 (Ganitumab) plus Metformin", "type": "DRUG" }, { "name": "MK-2206 with or without Trastuzumab", "type": "DRUG" }, { "name": "AMG 386 and Trastuzumab", "type": "DRUG" }, { "name": "T-DM1 and Pertuzumab", "type": "DRUG" }, { "name": "Pertuzumab and Trastuzumab", "type": "DRUG" }, { "name": "Ganetespib", "type": "DRUG" }, { "name": "ABT-888", "type": "DRUG" }, { "name": "Neratinib", "type": "DRUG" }, { "name": "PLX3397", "type": "DRUG" }, { "name": "Pembrolizumab - 4 cycle", "type": "DRUG" }, { "name": "Talazoparib plus Irinotecan", "type": "DRUG" }, { "name": "Patritumab and Trastuzumab", "type": "DRUG" }, { "name": "Pembrolizumab - 8 cycle", "type": "DRUG" }, { "name": "SGN-LIV1A", "type": "DRUG" }, { "name": "Durvalumab plus Olaparib", "type": "DRUG" }, { "name": "SD-101 + Pembrolizumab", "type": "DRUG" }, { "name": "Tucatinib plus trastuzumab and pertuzumab", "type": "DRUG" }, { "name": "Cemiplimab", "type": "DRUG" }, { "name": "Cemiplimab plus REGN3767", "type": "DRUG" }, { "name": "Trilaciclib with or without trastuzumab + pertuzumab", "type": "DRUG" }, { "name": "SYD985 ([vic-]trastuzumab duocarmazine)", "type": "DRUG" }, { "name": "Oral Paclitaxel + Encequidar + Dostarlimab (TSR-042) + Carboplatin with or without trastuzumab", "type": "DRUG" }, { "name": "Oral Paclitaxel + Encequidar + Dostarlimab (TSR-042) with or without trastuzumab", "type": "DRUG" }, { "name": "Amcenestrant", "type": "DRUG" }, { "name": "Amcenestrant + Abemaciclib", "type": "DRUG" }, { "name": "Amcenestrant + Letrozole", "type": "DRUG" }, { "name": "ARX788", "type": "DRUG" }, { "name": "ARX788 + Cemiplimab", "type": "DRUG" }, { "name": "VV1 + Cemiplimab", "type": "DRUG" }, { "name": "Datopotamab deruxtecan", "type": "DRUG" }, { "name": "Datopotamab deruxtecan + Durvalumab", "type": "DRUG" }, { "name": "Zanidatamab", "type": "DRUG" }, { "name": "Lasofoxifene", "type": "DRUG" }, { "name": "Z-endoxifen", "type": "DRUG" }, { "name": "ARV-471", "type": "DRUG" }, { "name": "ARV-471 + Letrozole", "type": "DRUG" }, { "name": "ARV-471 + Abemaciclib", "type": "DRUG" }, { "name": "Endoxifen + Abemaciclib", "type": "DRUG" }, { "name": "Rilvegostomig + TDXd", "type": "DRUG" }, { "name": "Dan222 + Niraparib", "type": "DRUG" }, { "name": "Sarilumab + Cemiplimab + Paclitaxel", "type": "DRUG" }, { "name": "GSK 5733584", "type": "DRUG" }, { "name": "GSK 5733584 + Dostarlimab", "type": "DRUG" }, { "name": "Ivonescimab (20mg/kg Q3W)", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "QuantumLeap Healthcare Collaborative", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 5000, "start_date": "2010-03-01", "completion_date": "2031-12", "has_results": false, "last_update_posted_date": "2026-05-06", "last_synced_at": "2026-10-10T10:15:52.789Z", "location_count": 42, "location_summary": "Birmingham, Alabama • Scottsdale, Arizona • Tucson, Arizona + 36 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Scottsdale", "state": "Arizona" }, { "city": "Tucson", "state": "Arizona" }, { "city": "Davis", "state": "California" }, { "city": "Duarte", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT01042379" } ] }